Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin

Table 1 Clinical characteristics of Pneumocystis jirovecii pneumonia cases

Characteristics	Patients, n (%)	Median value (range)
Demographics
Male/female	18/4
Age, median (range, yr)		61.18 ± 16.51
Underlying disease	22/22
Clinical manifestations
Fever	13/22
Cough	22/22
Dyspnea	22/22
Laboratory tests
WBC (normal 4 × 109–10 × 109/L)		9.69 ± 6.22
Percentage of neutrophils		0.82 ± 0.14
CRP (normal 0–8 mg/L)		79.69 ± 64.21
PCT (normal 0–0.5 ng/mL)		0.23 ± 0.21
LDH (normal 120–250 U/L)		408.23 ± 117.87
Oxygenation index		209.55 ± 35.03
CD4+ T lymphocyte counts		0.81 ± 0.52
Imaging
Diffuse ground glass opacity	19/22 (86.36%)
Streak like dense shadow	3/22 (13.64%)
Complete CT recovery in survivors	22/22 (100.0%)

CRP: C-reactive protein; CT: Computed tomography; PCT: Procalcitonin; WBC: White blood cell; LDH: Lactate dehydrogenase.